欧洲委员会已正式授予万达生物制药(Vanda Pharmaceuticals)旗下在研药物Imsidolimab用于治疗泛发性脓疱型银屑病的孤儿药资格认定。这一决定标志着该药物在罕见皮肤病领域获得了监管层面的重要认可,有望加速其后续的临床开发与上市审批进程。
欧洲委员会已正式授予万达生物制药(Vanda Pharmaceuticals)旗下在研药物Imsidolimab用于治疗泛发性脓疱型银屑病的孤儿药资格认定。这一决定标志着该药物在罕见皮肤病领域获得了监管层面的重要认可,有望加速其后续的临床开发与上市审批进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.